Capecitabine

Xeloda

Antineoplastic • Antimetabolite (fluoropyrimidine prodrug)

NTIHepatotoxic

Half-life

0.75 hours (5-FU terminal: 0.5-1 hour)

Protein Binding

<60%

Metabolized By

Carboxylesterase, Cytidine deaminase

External

Oral prodrug converted to 5-FU preferentially in tumor tissue; inhibits thymidylate synthase

Drug Class

Antineoplastic

Subclass

Antimetabolite (fluoropyrimidine prodrug)

Xeloda

Half-life

0.75 hours (5-FU terminal: 0.5-1 hour)

Time for plasma concentration to decrease by 50%

Protein Binding

<60%

Fraction bound to plasma proteins

Therapeutic Index

Narrow

Margin between therapeutic and toxic doses